shutterstock_690219232_katherine_welles
Katherine Welles / Shutterstock.com
16 September 2020AmericasSarah Morgan

Merck & Co to buy $1bn stake in Seattle Genetics

Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
21 September 2020   The Federal Court of Australia has rejected Boehringer Ingelheim’s animal health unit's attempt to stop the registration of a patent owned by Intervet International on various grounds.
Americas
14 September 2020   Gilead Sciences is set to acquire biopharmaceutical company Immunomedics in a $21 billion deal, further strengthening its oncology expertise.
Americas
28 May 2020   Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

More on this story

Biotechnology
21 September 2020   The Federal Court of Australia has rejected Boehringer Ingelheim’s animal health unit's attempt to stop the registration of a patent owned by Intervet International on various grounds.
Americas
14 September 2020   Gilead Sciences is set to acquire biopharmaceutical company Immunomedics in a $21 billion deal, further strengthening its oncology expertise.
Americas
28 May 2020   Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

More on this story

Biotechnology
21 September 2020   The Federal Court of Australia has rejected Boehringer Ingelheim’s animal health unit's attempt to stop the registration of a patent owned by Intervet International on various grounds.
Americas
14 September 2020   Gilead Sciences is set to acquire biopharmaceutical company Immunomedics in a $21 billion deal, further strengthening its oncology expertise.
Americas
28 May 2020   Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.